Literature DB >> 3965374

Endolymphatic stromal myosis: a case with positive estrogen and progesterone receptors and good response to progestins.

N Tsukamoto, T Kamura, K Matsukuma, M Imachi, H Uchino, T Saito, M Ono.   

Abstract

This report describes a case of recurrent and metastatic endolymphatic stromal myosis (ESM), which showed good response to progestin therapy. Metastatic lung nodules regressed after medroxyprogesterone acetate (MPA) treatment, recurred while MPA was stopped, and disappeared again when MPA was restarted. The levels of estrogen and progesterone receptors measured in the resected tumor amounted to 79.5 and 310 fmole/mg protein, respectively. Sex steroid hormone dependency of ESM was reviewed in the literature.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3965374     DOI： 10.1016/0090-8258(85)90132-5

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN： 0090-8258            Impact factor:   5.482


  7 in total

1.  Aromatase inhibitor anastrozole as a second-line hormonal treatment to a recurrent low-grade endometrial stromal sarcoma: a case report.

Authors:  Keiko Shoji; Katsutoshi Oda; Shunsuke Nakagawa; Kei Kawana; Toshiharu Yasugi; Yuji Ikeda; Yutaka Takazawa; Shiro Kozuma; Yuji Taketani
Journal:  Med Oncol       Date:  2010-03-31       Impact factor: 3.064

2.  Metastatic low-grade endometrial stromal sarcoma of the sigmoid colon three years after hysterectomy.

Authors:  Yuki Asada; Hajime Isomoto; Fumitaka Akama; Noriko Nomura; Chun-Yang Wen; Haruhiko Nakao; Ikuo Murata; Kan Toriyama; Shigeru Kohno
Journal:  World J Gastroenterol       Date:  2005-04-21       Impact factor: 5.742

3.  Prolonged long-term survival of low-grade endometrial stromal sarcoma patients with lung metastasis following treatment with medroxyprogesterone acetate.

Authors:  Kentaro Nakayama; Masako Ishikawa; Yutaka Nagai; Nobuo Yaegashi; Yoichi Aoki; Khoji Miyazaki
Journal:  Int J Clin Oncol       Date:  2010-03-10       Impact factor: 3.402

4.  Long-term survival of patients given hormonal therapy for metastatic endometrial stromal sarcoma.

Authors:  J-P Spano; J-C Soria; M Kambouchner; S Piperno-Neuman; F Morin; J-F Morere; A Martin; J-L Breau
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

5.  Expression of oestrogen and progesterone receptors in low-grade endometrial stromal sarcomas.

Authors:  O Reich; S Regauer; W Urdl; M Lahousen; R Winter
Journal:  Br J Cancer       Date:  2000-03       Impact factor: 7.640

6.  Letrozole as second-line hormonal treatment for recurrent low-grade endometrial stromal sarcoma: A case report and review of the literature.

Authors:  Kohei Nakamura; Kentaro Nakayama; Masako Ishikawa; Noriyoshi Ishikawa; Hiroshi Katagiri; Atsuko Katagiri; Tomoka Ishibashi; Emi Sato; Kohji Iida; Razia Sultana; Satoru Kyo
Journal:  Oncol Lett       Date:  2016-09-26       Impact factor: 2.967

Review 7.  Novel approaches in cancer treatment: preclinical and clinical development of small non-coding RNA therapeutics.

Authors:  Rossana Cuciniello; Stefania Filosa; Stefania Crispi
Journal:  J Exp Clin Cancer Res       Date:  2021-12-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.